Newsroom

NK cells complexed with bispecific antibody yield high response rates in patients with lymphoma

April 04, 2025

HOUSTON ― A novel cell therapy approach using cord blood-derived natural killer (NK) cells pre-complexed with AFM13, or acimtamig, a CD30/CD16A bispecific antibody, was safe and generated strong response rates for patients with refractory CD30-positive lymphomas, according to a new study from The University of Texas MD Anderson Cancer Center.

Results from the Phase I trial, published today in Nature Medicine, demonstrated an overall...

MD Anderson breaks ground on new Sugar Land location

BY McKenna Waldrop

March 31, 2025

The University of Texas MD Anderson Cancer Center today broke ground on a new 470,000-square-foot facility in Sugar Land, bringing a range...

Surgery may not be necessary to treat invasive breast cancer

BY Jamie Mauracher

March 27, 2025

Surgery may not be the best next course of treatment for patients with early-stage breast cancer who had a complete response to neoadjuvant...

Two MD Anderson researchers elected AAAS Fellows

March 26, 2025

In recognition of their significant achievements to advance cancer care and research, Lauren Byers, M.D., and Paul Scheet, Ph.D., from The University of Texas MD Anderson Cancer Center have been elected fellows of the American Association for the Advancement of Science (AAAS).

This distinction stands as one of the highest accolades within the scientific research community. AAAS’s tradition of recognizing leading scientists...